These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26054088)

  • 41. Brentuximab vedotin: first-line agent for advanced Hodgkin lymphoma.
    Cao H; Yamamoto K; Yang LX; Weber R
    Anticancer Res; 2013 Sep; 33(9):3879-85. PubMed ID: 24023323
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
    Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
    Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.
    Carlo-Stella C; Ricci F; Dalto S; Mazza R; Malagola M; Patriarca F; Viviani S; Russo D; Giordano L; Castagna L; Corradini P; Santoro A
    Oncologist; 2015 Mar; 20(3):323-8. PubMed ID: 25669663
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Five-Year Survival Data Demonstrating Durable Responses From a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma.
    Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):6. PubMed ID: 27007002
    [No Abstract]   [Full Text] [Related]  

  • 45. TARC Predicts PET-Normalization and Event Free Survival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated With Brentuximab Vedotin.
    Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):10-2. PubMed ID: 27007005
    [No Abstract]   [Full Text] [Related]  

  • 46. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
    Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
    Mehta A; Forero-Torres A
    Curr Oncol Rep; 2015 Sep; 17(9):41. PubMed ID: 26194424
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma.
    Arora A; Bhatt VR; Liewer S; Armitage JO; Bociek RG
    Eur J Haematol; 2015 Oct; 95(4):361-4. PubMed ID: 25892213
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A rare case of orbital hodgkin lymphoma demonstrating therapeutic response to a novel systemic medication.
    Wajda BN; Rabinowitz MP
    Orbit; 2017 Feb; 36(1):52-54. PubMed ID: 27824517
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transient loss of detectable HIV-1 RNA following brentuximab vedotin anti-CD30 therapy for Hodgkin lymphoma.
    Wang CC; Thanh C; Gibson EA; Ball-Burack M; Hogan LE; Descours B; Jones N; Carvidi AB; Munter S; Bakkour S; Busch MP; Milush JM; Deeks SG; Henrich TJ
    Blood Adv; 2018 Dec; 2(23):3479-3482. PubMed ID: 30530753
    [TBL] [Abstract][Full Text] [Related]  

  • 51. FDA approves brentuximab vedotin for Hodgkin lymphoma and systemic anaplastic large-cell lymphoma.
    Oncology (Williston Park); 2011 Sep; 25(10):904. PubMed ID: 22010386
    [No Abstract]   [Full Text] [Related]  

  • 52. Brentuximab vedotin in anaplastic large cell lymphoma.
    Skarbnik AP; Smith MR
    Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.
    Theurich S; Malcher J; Wennhold K; Shimabukuro-Vornhagen A; Chemnitz J; Holtick U; Krause A; Kobe C; Kahraman D; Engert A; Scheid C; Chakupurakal G; Hallek M; von Bergwelt-Baildon M
    J Clin Oncol; 2013 Feb; 31(5):e59-63. PubMed ID: 23269992
    [No Abstract]   [Full Text] [Related]  

  • 54. Brentuximab vedotin in systemic T-cell lymphoma.
    Oki Y; Younes A
    Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma.
    Flerlage JE; Metzger ML; Wu J; Panetta JC
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1217-1223. PubMed ID: 27837256
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical roundtable monograph: CD30 in lymphoma: its role in biology, diagnostic testing, and targeted therapy.
    Sotomayor EM; Young KH; Younes A
    Clin Adv Hematol Oncol; 2014 Apr; 12(4 Suppl 10):1-22. PubMed ID: 24870054
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas.
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):3-4. PubMed ID: 24870871
    [No Abstract]   [Full Text] [Related]  

  • 58. [Brentuximab vedotin and cord blood transplantation for primary refractory Hodgkin lymphoma following autologous hematopoietic stem cell transplantation].
    Meshitsuka S; Suzuki K; Igeta Y; Kawai S; Kumasaka T; Tsukada N
    Rinsho Ketsueki; 2015 Jun; 56(6):699-704. PubMed ID: 26256882
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and efficacy of brentuximab vedotin (SGN-35) in Hodgkin lymphoma patients undergoing reduced intensity allogeneic stem cell transplant following a relapse after autologous transplant.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):20. PubMed ID: 25768999
    [No Abstract]   [Full Text] [Related]  

  • 60. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
    Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
    JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.